Skip to main content
Update Location

My Location

Update your location to show providers, locations, and services closest to you.

Enter a zip code
Or
Select a campus/region

GORE? EXCLUDER? Conformable AAA Endoprosthesis in the Treatment of Abdominal Aortic Aneurysms

  • Status
    Accepting Candidates
  • Age
    21 Years - N/A
  • Sexes
    All
  • Healthy Volunteers
    No

Objective

The purpose of the study is to assess the safety and effectiveness of the GORE® EXCLUDER® Conformable AAA Endoprosthesis to treat an infrarenal aneurysm located in the abdominal aorta. Performance of the GORE® EXCLUDER® Conformable AAA Endoprosthesis will be judged by separate performance goals.

Description

The study design is a prospective, nonrandomized, international, multicenter study comprised of two parallel substudies. The total subject population is 175 subjects with 80 subjects assigned to the Short Neck Substudy and 95 subjects to the High Neck Angulation Substudy.

This clinical study will include up to fifty-six sites in the US. Each enrolled subject will undergo periodic follow-up evaluations involving physical exams and contrast-enhanced computed tomography (CT) scans at specific, protocol-defined intervals for a period of five years following the GORE® EXCLUDER® Conformable AAA Endoprosthesis implant. Each Substudy will be evaluated and reported independently from each other according to the Safety and Effectiveness Endpoints. No comparative analyses between these substudies are planned.

Details

Full study title Assessment of the GORE? EXCLUDER? Conformable AAA Endoprosthesis (CEXC Device) in the Treatment of Abdominal Aortic Aneurysms
Protocol number OCR20218
ClinicalTrials.gov ID NCT02489539
Phase N/A

Eligibility

Inclusion Criteria:

  1. AAA meeting any of the following criteria:

    • Maximum diameter ≥50 mm

    • Rapid growth (>5 mm in a 6 month period)

    • Non-ruptured AAA presenting with clinical symptoms

  2. Adequate anatomy to receive the GORE® EXCLUDER® Conformable AAA Endoprosthesis,

Including:

  • Adequate iliac / femoral access

  • Infrarenal aortic neck diameter 16-32 mm

  • Infrarenal aortic neck length ≥10 mm

  • Aortic neck angle ≤ 90˚

  • Distal iliac artery seal zone ≥10 mm

  • Iliac artery diameter 8-25 mm

  1. An Informed Consent Form (ICF) signed by Subject

  2. Male or infertile female

  3. Able to comply with Protocol requirements including following-up

  4. Life expectancy > 2 years

  5. Age ≥ 21 years

Exclusion Criteria:

  1. Mycotic or ruptured aneurysm

  2. Known concomitant thoracic aortic aneurysm which requires surgical intervention

  3. Renal insufficiency defined as creatinine > 2. 5 mg/dL or patient undergoing dialysis

  4. New York Heart Association (NYHA) class IV

  5. Aneurysmal, dissected, heavily calcified, or heavily thrombosed landing zone(s)

  6. Severely tortuous or stenotic iliac and / or femoral arteries

  7. Patient has body habitus or other medical condition which prevents adequate delineation of the aorta

  8. Participating in another investigational device or drug study within 1 year of treatment

  9. Systemic infection which may increase the risk of endovascular graft infection

  10. Known degenerative connective tissue disease, e.g., Marfan or Ehler-Danlos Syndrome

  11. Planned concomitant surgical procedure or major surgery within 30 days of treatment

date

  1. Known history of drug abuse

  2. Known sensitivities or allergies to the device materials

Lead researcher

Participate in a study

Here are some general steps to consider when participating in a research study:

  1. Step
    1

    Contact the research team

    Call or email the research team listed within the specific clinical trial or study to let them know that you're interested. A member of the research team, such as the researcher or study coordinator, will be available to tell you more about the study and to answer any questions or concerns you may have.

    Primary contact

  2. Step
    2

    Get screened to confirm eligibility

    You may be asked to take part in prescreening to make sure you are eligible for a study. The prescreening process ensures it is safe for you to participate. During the prescreening process, you will be asked some questions and you may also be asked to schedule tests or procedures to confirm your eligibility.

  3. Step
    3

    Provide your consent to participate

    If you are eligible and want to join the clinical trial or study, a member of the research team will ask for your consent to participate. To give consent, you will be asked to read and sign a consent form for the study. This consent form explains the study's purpose, procedures, risks, benefits and provides other important information, such as the study team's contact information.

  4. Step
    4

    Participate

    If you decide to participate in a clinical trial or study, the research team will keep you informed of the study requirements and what you will need to do to throughout the study. For some trials or studies, your health care provider may work with the research team to ensure there are no conflicts with other medications or treatments.